Patents Assigned to Lutris Pharma Ltd.
  • USE OF TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF EPIDERMAL GROWTH FACTOR RECEPTOR DOWNSTREAM EFFECTORS - INDUCED CUTANEOUS REACTIONS
    Publication number: 20230321106
    Abstract: Pharmaceutical topical compositions comprising compound of Formula IV and method of using pharmaceutical topical compositions comprising compound of Formula IV for the treatment or prevention of EGFR inhibitor, PI3K inhibitor, MEK inhibitor and/or HER dimerization inhibitor-induced acneiform lesions in a subject in need thereof are provided.
    Type: Application
    Filed: June 13, 2023
    Publication date: October 12, 2023
    Applicant: Lutris Pharma Ltd.
    Inventors: Noa Shelach, Galit Zelinger
  • Use of topical BRAF inhibitor compositions for treatment of radiation dermatitis
    Patent number: 11439648
    Abstract: The present invention discloses methods of treatment, prevention and/or amelioration of radiation dermatitis caused by radiotherapy, by administration to a subject in need thereof of a topical composition comprising a therapeutically or prophylactically effective amount of at least one BRaf inhibitor of this invention, thus treating, preventing and/or ameliorating the effects of radiation dermatitis.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: September 13, 2022
    Assignee: Lutris Pharma Ltd.
    Inventors: Noa Shelach, Noa Lowenton-Spier
  • BRaf inhibitors and use thereof for treatment of cutaneous reactions
    Patent number: 11339163
    Abstract: The present invention discloses novel BRaf inhibitors, compositions comprising these BRaf inhibitors and uses thereof for the treatment, amelioration and/or prevention of cutaneous reactions.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: May 24, 2022
    Assignee: Lutris Pharma Ltd.
    Inventor: Noa Shelach
  • Methods of screening BRaf inhibitors for treating cutaneous reactions
    Patent number: 11197861
    Abstract: The invention discloses methods for screening out of a BRaf inhibitor population, suitable BRaf inhibitors as candidates for clinical development of drugs for treating and/or preventing cutaneous reaction caused by treatment with EGFR inhibitor and/or PI3K inhibitors.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: December 14, 2021
    Assignee: Lutris Pharma Ltd.
    Inventor: Noa Shelach
  • BRaf inhibitors and use thereof for treatment of cutaneous reactions
    Patent number: 10927112
    Abstract: The present invention discloses novel BRaf inhibitors of formula (I), (II) or (III), wherein R is defined as set forth in the specification, compositions comprising these BRaf inhibitors and uses thereof for the treatment, amelioration and/or prevention of cutaneous reactions.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: February 23, 2021
    Assignee: Lutris Pharma Ltd.
    Inventor: Noa Shelach
  • Use of BRaf inhibitors for treating cutaneous reactions
    Patent number: 10632123
    Abstract: The invention discloses compositions comprising BRaf inhibitors and uses thereof for treating and/or preventing by topical or systemic administration cutaneous conditions caused by treatment with EGFR inhibitors and/or PI3K inhibitors.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: April 28, 2020
    Assignee: Lutris Pharma Ltd.
    Inventor: Noa Shelach